AMD To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Friday
Analysts cut targets for GWW, IE and COST, while raising targets for OKTA, AXGN, ZS and DRI; ratings remained unchanged.
Stocks · News reference
Raymond James Maintains Outperform on Axogen, Raises Price Target to $53
Raymond James analyst Jayson Bedford maintains Axogen (NASDAQ:AXGN) with a Outperform and raises the price target from $48 to $53.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K/A filing — Axogen, Inc. (AXGN)
Filed: 2026-09-10 AccNo: 0001628280-26-061393 Size: 3 MB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair
Axogen is acquiring BioCircuit Technologies for $200 million to add sutureless NerveTape to its portfolio, funded by a public stock offering.